AssayIndex
Reports by quarter

Reports submitted in 2025-Q1 · page 2

Anomaly rule set expanded from seven rules to eleven. Median purity for the quarter is 99.14 % area, n=664. Read the 2025-Q1 state-of-the-index report →

672 records17 pagesmedian on this page 99.18 %updated 30 Jul 2026
ReportCompoundSupplierLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2025-020597SermorelinSSASSA-2409-X7161Janoshik2025-Q198.354.6692.8Buyer-sourced0PASS
AX-2025-020292BPC-157GGPepsGGPE-2502-S2559VendorInvestigate2025-Q198.322.7892.8Buyer-sourced0PASS
AX-2025-020065P21SWBSWB-2408-T8372Janoshik2025-Q199.748.5698.6Buyer-sourced0PASS
AX-2025-019684Melanotan IITFCTFC-2410-R2237Medutest2025-Q199.335.5596.0Buyer-sourced0PASS
AX-2025-019154LL-37SinoPepSNP-2411-X3762Janoshik2025-Q198.652.63—Buyer-sourced1MARGINAL
AX-2025-018920CJC-1295 with DACTFSTFS-{CAT}-9795VendorInvestigate2025-Q199.002.86—Laboratory-retained2MARGINAL
AX-2025-018761BPC-157QSCQSC-2412-D7527Nordanalyt2025-Q199.485.71—Buyer-sourced0PASS
AX-2025-019665AfamelanotideTFCTFC-2502-Y2346Janoshik2025-Q199.184.7799.2Buyer-sourced1MARGINAL
AX-2025-019652GHRP-2TFCTFC-2502-D2333Kestrel2025-Q199.615.3688.7Buyer-sourced1MARGINAL
AX-2025-019534IpamorelinTFCTFC-2408-T9161Janoshik2025-Q198.874.4399.2Buyer-sourced0FAIL
AX-2025-018954TirzepatideASYASY-{CAT}-1244Janoshik2025-Q198.804.86106.3Buyer-sourced0PASS
AX-2025-018842PT-141 (Bremelanotide)FGPFGP-2409-W9076PeptideMeter2025-Q199.694.56—Buyer-sourced0PASS
AX-2025-020988CJC-1295 with DACWXTWXT-2409-Y3760Janoshik2025-Q196.834.78—Buyer-sourced1FAIL
AX-2025-020897MK-677 (Ibutamoren mesylate)WXTWXT-2502-F2050Janoshik2025-Q199.204.3991.7Buyer-sourced1FAIL
AX-2025-018664TirzepatideQSCQSC-2410-R5814Nordanalyt2025-Q199.314.88—Buyer-sourced0PASS
AX-2025-018472TirzepatideWWBWWB-2502-U2990Janoshik2025-Q199.053.24—Buyer-sourced1MARGINAL
AX-2025-020772SemaglutideSGNSGN-2410-D9265Kestrel2025-Q198.644.39—Buyer-sourced0PASS
AX-2025-020513MOTS-cSSASSA-2501-M6154Medutest2025-Q198.812.96—Supplier-supplied0PASS
AX-2025-019657AfamelanotideTFCTFC-2502-Y2346VendorInvestigate2025-Q199.474.61—Buyer-sourced1MARGINAL
AX-2025-019180Enclomiphene citrateSinoPepSNP-2412-F3914Nordanalyt2025-Q199.505.1196.4Buyer-sourced1FAIL
AX-2025-018824BPC-157FGPFGP-2409-Y8596Medutest2025-Q199.934.9789.0Buyer-sourced1MARGINAL
AX-2025-021041CJC-1295 (no DAC)BCHBCH-2502-A4465VendorInvestigate2025-Q198.044.58—Buyer-sourced1MARGINAL
AX-2025-020824ThymalinCPCCPC-2501-V2021Medutest2025-Q1N/A6.58—Buyer-sourced1N/A
AX-2025-020641TirzepatideGL BiochemGLBI-2412-R8446PeptideMeter2025-Q198.984.6194.7Buyer-sourced0PASS
AX-2025-020123MGFERPERP-2501-B8503Janoshik2025-Q198.513.0893.0Buyer-sourced0PASS
AX-2025-019668AfamelanotideTFCTFC-2502-Y2346Janoshik2025-Q199.135.02—Buyer-sourced1MARGINAL
AX-2025-019663AfamelanotideTFCTFC-2502-Y2346Janoshik2025-Q199.285.01—Buyer-sourced1MARGINAL
AX-2025-018520SemaglutideWWBWWB-2410-J3284Nordanalyt2025-Q199.633.3998.7Buyer-sourced0PASS
AX-2025-019822KPVHomopeptideHOMO-2411-P5026Janoshik2025-Q199.754.8588.7Laboratory-retained1MARGINAL
AX-2025-019819KPVHomopeptideHOMO-2411-P5026PeptideMeter2025-Q199.354.7791.6Buyer-sourced0FAIL
AX-2025-019757SemaglutideHomopeptideHOMO-2501-D4523Janoshik2025-Q199.495.4890.8Buyer-sourced0PASS
AX-2025-019141TesamorelinGSPGSP-2501-G3708VendorInvestigate2025-Q198.134.76—Buyer-sourced0PASS
AX-2025-018854DihexaFGPFGP-2408-S8496Medutest2025-Q199.617.10—Buyer-sourced0PASS
AX-2025-020257Enclomiphene citrateGGPepsGGPE-2410-S2226Medutest2025-Q198.033.71—Buyer-sourced0FAIL
AX-2025-020017AOD-9604SWBSWB-2502-N7040PeptideMeter2025-Q199.004.3891.1Buyer-sourced0PASS
AX-2025-019372GHRP-2HYBHYB-2501-R7240PeptideMeter2025-Q199.824.2695.9Buyer-sourced0PASS
AX-2025-018826BPC-157FGPFGP-2409-Y8596Janoshik2025-Q199.915.16100.0Buyer-sourced0PASS
AX-2025-018421SemaglutideWWBWWB-2501-S2183VendorInvestigate2025-Q199.703.75—Buyer-sourced0PASS
AX-2025-020647TirzepatideGL BiochemGLBI-2412-R8446Janoshik2025-Q198.815.24—Buyer-sourced0PASS
AX-2025-020261Enclomiphene citrateGGPepsGGPE-2410-S2226VendorInvestigate2025-Q197.743.73—Buyer-sourced0FAIL